These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2239494)

  • 1. Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease.
    Jori MC; Franceschi M; Giusti MC; Canal N; Piolti R; Frattola L; Bassi S; Calloni E; Mamoli A; Camerlingo M
    Adv Neurol; 1990; 53():539-43. PubMed ID: 2239494
    [No Abstract]   [Full Text] [Related]  

  • 2. Cabergoline plasma concentration is increased during concomitant treatment with itraconazole.
    Christensen J; Dupont E; ØStergaard K
    Mov Disord; 2002 Nov; 17(6):1360-2. PubMed ID: 12465083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabergoline: a long-acting dopamine agonist in Parkinson's disease.
    Lera G; Vaamonde J; Muruzabal J; Obeso JA
    Ann Neurol; 1990 Oct; 28(4):593-4. PubMed ID: 2252377
    [No Abstract]   [Full Text] [Related]  

  • 4. Cabergoline : a review of its use in the treatment of Parkinson's disease.
    Curran MP; Perry CM
    Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
    Pfeiffer RF; Wilken K; Glaeske C
    Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
    Schneider E; Hubener K; Fischer PA
    Adv Neurol; 1984; 40():527-9. PubMed ID: 6695631
    [No Abstract]   [Full Text] [Related]  

  • 8. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
    Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
    Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term tolerability of high dose ergoline derived dopamine agonist therapy for the treatment of Parkinson's disease.
    Navan P; Bain PG
    J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):602-3. PubMed ID: 12397168
    [No Abstract]   [Full Text] [Related]  

  • 10. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
    Frans E; Dom R; Demedts M
    Eur Respir J; 1992 Feb; 5(2):263-5. PubMed ID: 1348483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K; Needleman F; Macphee G; Grosset D
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
    Arnold G; Trenkwalder C; Schwarz J; Oertel WH
    Mov Disord; 1994 Mar; 9(2):238-40. PubMed ID: 7910949
    [No Abstract]   [Full Text] [Related]  

  • 13. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
    Bélanger N; Grégoire L; Hadj Tahar A; Bédard PJ
    Mov Disord; 2003 Dec; 18(12):1436-41. PubMed ID: 14673879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease.
    Lees AJ
    Adv Neurol; 1990; 53():475-82. PubMed ID: 2239487
    [No Abstract]   [Full Text] [Related]  

  • 15. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
    Del Dotto P; Colzi A; Pardini C; Lucetti C; Dubini A; Grimaldi R; Bonuccelli U
    J Neural Transm Suppl; 1995; 45():259-65. PubMed ID: 8748633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
    Ohno H; Nakajima M; Fujioka S; Iwamoto K; Kawamura M
    J Clin Neurosci; 2009 Jun; 16(6):790-2. PubMed ID: 19286385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
    Wolters EC; Horstink MW; Roos RA; Jansen EN
    Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical pharmacokinetics of cabergoline.
    Del Dotto P; Bonuccelli U
    Clin Pharmacokinet; 2003; 42(7):633-45. PubMed ID: 12844325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.